BrainParrot

Break the chain

GS2Full notePublished: · Updated:

Source: The Hindu, 7 October 2026

Summary

  • The editorial argues that India's leprosy burden has fallen over the last decade, but continued transmission in many pockets threatens the targets of the National Strategic Plan (NSP) and Roadmap for Leprosy 2023–2027.
  • It says the state should prioritise interrupting transmission over lowering prevalence. It should also resist easing detection or revising its elimination targets.

UPSC relevance: GS2/GS3 — Health, disease elimination, NLEP

Key facts for Prelims

  • National-level elimination of leprosy as a public health problem was achieved in 2005 (prevalence below 1 per 10,000, the WHO criterion).
  • NLEP is a centrally sponsored scheme under the National Health Mission. NSP & Roadmap for Leprosy: 2023–2027.
  • Post-exposure prophylaxis uses single-dose rifampicin for contacts of cases.
  • Multi-Drug Therapy (MDT) is the standard treatment (rifampicin, dapsone, clofazimine).
  • Leprosy was declared a notifiable disease in 2025. Nikusth 2.0 is the web portal for case reporting.
  • Terms: prevalence, incidence, Grade-2 disability (G2D), "interruption of transmission".
  • The MIP vaccine is under consideration for use in patients deemed highly infectious.

Data and details

  • The prevalence of leprosy among adults and children, and the Grade-2 disability rate, have dropped over the last decade. Continued transmission in many pockets constrains the NSP targets.
  • By 2005, national prevalence was under 1 case per 10,000, and WHO recognised India as having eliminated leprosy as a public health problem.
  • Disability began to rise in the early 2010s, which prompted door-to-door screening.
  • The article gives a figure of "around 46%" tied to children's cases in 2025. Its wording is unclear, but it is used to argue that the child and adult programmes must move in tandem.
  • Chhattisgarh, Jharkhand, Odisha and Maharashtra bear disproportionate shares of the national burden.
  • The 2025–26 National Leprosy Elimination Programme report: only 148 districts have achieved "interruption of transmission" (pending field verification), against a projected 300.
  • In 2025–26, workers screened more than 70 crore people in highly endemic areas and detected 24,367 cases.
  • ASHA workers flagged nearly 40 lakh suspected cases, of which 48,027 were confirmed.
  • Single-dose rifampicin PEP reached 91.1% of the 16.9 lakh likely contacts.
  • Overshoot against projections in 2025–26: overall incidence 41%, incidence among children 91.6%, and Grade-2 disability rate 34%.
  • Digital surveillance has been operationalised. The government is deliberating on the MIP vaccine for highly infectious patients.

Static–dynamic linkage

  • "Elimination as a public health problem" is a prevalence threshold. It is not the same as interrupting transmission or eradication. A disease can fall below the threshold, as leprosy did in India in 2005, while new infections continue.
  • Prevalence reflects the registered treatment pool, and shorter treatment regimens shrink that pool. Incidence, child cases and Grade-2 disability reflect ongoing transmission and late diagnosis. This is the core of the editorial's argument.
  • Post-exposure prophylaxis (PEP), active case detection, digital surveillance and stigma reduction are the main tools.

Syllabus mapping: GS2 – Social Justice: health, vulnerable groups, government schemes | GS3 – S&T: health technology (vaccines, prophylaxis, digital surveillance) | Prelims – SciTech (health), Society

Background primer

National Leprosy Eradication Programme (NLEP) and the NSP & Roadmap 2023–27

What it is:
NLEP is a centrally sponsored scheme under the National Health Mission. It provides free services for prevention, diagnosis, treatment and rehabilitation through public health facilities.
Why it matters:
The plan aims to interrupt transmission rather than only reduce registered prevalence. It relies on accelerated case detection, intensified surveillance, chemoprophylaxis (PEP) and digital tools.

Additional context

  • The new case detection rate fell from 9.73 per lakh in 2014–15 to 7.0 per lakh in 2024–25. The share of child cases among new cases fell from 9.04% to 4.68%.
  • Leprosy Case Detection Campaigns (LCDC) are door-to-door surveys, especially in high-endemic areas, and have been conducted twice a year. Leprosy screening is converged with Ayushman Bharat for people above 30 and with RBSK for children.
  • DGHS lists a revised treatment regimen implemented across India in 2025.
  • DGHS records that after national elimination in 2005, the vertically run NLEP services were integrated into the general health system under the National Rural Health Mission. This matches the editorial's point about folding leprosy surveillance into general health services.

Mains dimensions

  • A policy lapse after "elimination": After the 2005 milestone the government grew complacent and folded leprosy surveillance into the general health system. Multi-drug regimens shortened the time patients stayed registered. Prevalence fell while transmission continued, and Grade-2 disability rose in the early 2010s.
  • Wrong metric vs. right metric: The NSP focuses on cutting transmission, in line with WHO. The editorial wants prevalence treated as a secondary outcome. The evidence is that incidence overshot projections by 41%, child incidence by 91.6% and Grade-2 disability by 34%. Only 148 districts against a projected 300 have reached interruption (pending verification).
  • Regional inequity: Chhattisgarh, Jharkhand, Odisha and Maharashtra carry disproportionate shares. This argues for State-specific and district-specific focus, including settings where late diagnosis and transmission persist.
  • Strong outreach, weak last mile: 70 crore screened, 24,367 cases in endemic areas, about 40 lakh ASHA-flagged suspects with 48,027 confirmed, and 91.1% PEP coverage of 16.9 lakh contacts show strong coverage. Care gaps remain: nerve damage is often present at first presentation because of stigma, and many clinicians misdiagnose leprosy as a skin condition.
  • Stigma and capacity: Stigma delays care. Frontline and clinician training matters as much as drugs.
  • Way forward: Double down on interrupting transmission. Do not ease detection or revise targets. Invest to meet the 2026–27 projections. Concentrate effort where late diagnosis and transmission persist. Deploy digital surveillance and consider vaccine options (MIP).

Possible Mains question

**GS2, 15 marks:** "India eliminated leprosy as a public health problem in 2005, yet transmission continues. Examine the reasons and evaluate the National Strategic Plan and Roadmap for Leprosy (2023–27) in addressing them."

Related topics

  • National Health Mission; Integrated Disease Surveillance Programme; Ayushman Bharat – HWCs
  • WHO Global Leprosy Strategy 2021–2030; neglected tropical diseases roadmap; SDG 3
  • Disease elimination vs. eradication (smallpox, polio, TB elimination programme)
  • Rights of Persons with Disabilities Act, 2016; stigma and discrimination laws
  • ASHA workers and community health delivery

Topics: GS2Sci & Tech

How we write and check these notes →

All current affairs of 7 October 2026 → · UPSC Current Affairs